In vitro activity of dolutegravir against wild-type and integrase inhibitor-resistant HIV-2

Retrovirology

Volumn 12, Issue 1, 2015, Pages

  Smith, Robert A ^a   Raugi, Dana N ^a   Pan, Charlotte ^a   Sow, Salif ^b   Seydi, Moussa ^b   Mullins, James I ^a   Gottlieb, Geoffrey S ^a   Toure, Macoumba ^c   Ba, Selly ^c   Badiane, Ndeye Mery Dia ^c   Fortes, Louise ^c   Ndour, Cheikh T ^c   Ndour, Jacques ^c   Niasse F , Fatou ^c   Sall, Fatima ^c   Traore, Fatou ^c   Faye, Khadim ^c   Chablis, Sophie ^c   Sy, Marie Pierre ^c   Diaw, Bintou ^c   Ndoye, Mbaye ^c   Diop, Amadou Bale ^c   Diome, Marianne Fadam ^c   Niang, Alassane ^d   Ibrahima, ElHadji ^d   Cisse, Ousseynou ^d   Diatta, Jean Philippe ^d   Bakhoum, Raphael ^d   Gomis, Juliette ^d   Hawes, Stephen ^a   Kenney, Donna ^a   Stern, Kenney ^a   Feng, Qinghua ^a   Lin, John ^a   Cherne, Steve ^a   Kiviat, Nancy ^a   Church, Brad ^a   Coyne, Matthew ^a   Hernandez, Alexandra ^a   Parker, Kara ^a   Blankenship, Lindsey ^a   Oakes, Mariah ^a   Olson, Julia ^a   Leong, Sally ^a   more..

^a UNIVERSITY OF WASHINGTON   (United States)

^b CHNU Fann   (Senegal)

^c Centre Hospitalier Universitaire Dakar   (Senegal)

^d Region Medicale de Ziguinchor   (Senegal)

Author keywords

[No Author keywords available]

Indexed keywords

DOLUTEGRAVIR; ELVITEGRAVIR; INTEGRASE; RALTEGRAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; FUSED HETEROCYCLIC RINGS;

AMINO ACID SUBSTITUTION; ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CROSS RESISTANCE; EC50; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; IN VITRO STUDY; NONHUMAN; PHENOTYPE; SITE DIRECTED MUTAGENESIS; T LYMPHOCYTE; VIRUS ISOLATION; WILD TYPE; DRUG EFFECTS; MICROBIAL SENSITIVITY TEST;

HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2;

ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; HETEROCYCLIC COMPOUNDS, 3-RING; HIV-1; HIV-2; HUMANS; MICROBIAL SENSITIVITY TESTS;

EID: 84924108880     PISSN: None     EISSN: 17424690     Source Type: Journal    
DOI: 10.1186/s12977-015-0146-8     Document Type: Article

References (73)

1. de Silva TI, Cotten M, Rowland-Jones SL. HIV-2: the forgotten AIDS virus. Trends Microbiol. 2008;16:588-95.
2. Cot MC, Poulain M, Delagneau JF, Peeters M, Brun-Vezinet F. Dual HIV-1 and HIV-2 infection in West Africa supported by synthetic peptide analysis. AIDS Res Hum Retroviruses. 1988;4:239-41.
3. Evans LA, Moreau J, Odehouri K, Seto D, Thomson-Honnebier G, Legg H, et al. Simultaneous isolation of HIV-1 and HIV-2 from an AIDS patient. Lancet. 1988;2:1389-91.
4. Rayfield M, De Cock K, Heyward W, Goldstein L, Krebs J, Kwok S, et al. Mixed human immunodeficiency virus (HIV) infection in an individual: demonstration of both HIV type 1 and type 2 proviral sequences by using polymerase chain reaction. J Infect Dis. 1988;158:1170-6.
5. Heitzinger K, Sow PS, Dia Badiane NM, Gottlieb GS, N'Doye I, Toure M, et al. Trends of HIV-1, HIV-2 and dual infection in women attending outpatient clinics in Senegal, 1990-2009. Int J STD AIDS. 2012;23:710-6.
6. Raugi DN, Gottlieb GS, Sow PS, Toure M, Sall F, Gaye A, et al. HIV-1 outcompetes HIV-2 in dually infected Senegalese individuals with low CD4(+) cell counts. AIDS. 2013;27:2441-50.
7. Gottlieb GS, Badiane NM, Hawes SE, Fortes L, Toure M, Ndour CT, et al. Emergence of multiclass drug-resistance in HIV-2 in antiretroviral-treated individuals in Senegal: implications for HIV-2 treatment in resource-limited West Africa. Clin Infect Dis. 2009;48:476-83.
8. Charpentier C, Eholie S, Anglaret X, Bertine M, Rouzioux C, Avettand-Fenoel V, et al. Genotypic resistance profiles of HIV-2-treated patients in West Africa. AIDS. 2014;28:1161-9.
9. Okomo U, Togun T, Oko F, Peterson K, Townend J, Peterson I, et al. Treatment outcomes among HIV-1 and HIV-2 infected children initiating antiretroviral therapy in a concentrated low prevalence setting in West Africa. BMC Pediatr. 2012;12:95.
10. Jallow S, Alabi A, Sarge-Njie R, Peterson K, Whittle H, Corrah T, et al. Virological response to highly active antiretroviral therapy in patients infected with human immunodeficiency virus type 2 (HIV-2) and in patients dually infected with HIV-1 and HIV-2 in the Gambia and emergence of drug-resistant variants. J Clin Microbiol. 2009;47:2200-8.
11. Benard A, van Sighem A, Taieb A, Valadas E, Ruelle J, Soriano V, et al. Immunovirological response to triple nucleotide reverse-transcriptase inhibitors and ritonavir-boosted protease inhibitors in treatment-naive HIV-2-infected patients: The ACHIEV2E Collaboration Study Group. Clin Infect Dis. 2011;52:1257-66.
12. Menendez-Arias L, Alvarez M. Antiretroviral therapy and drug resistance in human immunodeficiency virus type 2 infection. Antiviral Res. 2014;102:70-86.
13. Peterson K, Rowland-Jones S. Novel agents for the treatment of HIV-2 infection. Antivir Ther. 2012;17:435-8.
14. Smith RA, Raugi DN, Kiviat NB, Hawes SE, Mullins JI, Sow PS, et al. Phenotypic susceptibility of HIV-2 to raltegravir: integrase mutations Q148R and N155H confer raltegravir resistance. AIDS. 2011;25:2235-41.
15. Smith RA, Raugi DN, Pan C, Coyne M, Hernandez A, Church B, et al. Three main mutational pathways in HIV-2 lead to high-level raltegravir and elvitegravir resistance: implications for emerging HIV-2 treatment regimens. PLoS One. 2012;7:e45372.
16. Roquebert B, Damond F, Collin G, Matheron S, Peytavin G, Benard A, et al. HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitro. J Antimicrob Chemother. 2008;62:914-20.
17. Andreatta K, Miller MD, White KL. HIV-2 antiviral potency and selection of drug resistance mutations by the integrase strand transfer inhibitor elvitegravir and NRTIs emtricitabine and tenofovir in vitro. J Acquir Immune Defic Syndr. 2013;62:367-74.
18. Shimura K, Kodama E, Sakagami Y, Matsuzaki Y, Watanabe W, Yamataka K, et al. Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137). J Virol. 2008;82:764-74.
19. Peterson K, Ruelle J, Vekemans M, Siegal FP, Deayton JR, Colebunders R. The role of raltegravir in the treatment of HIV-2 infections: evidence from a case series. Antivir Ther. 2012;17:1097-100.
20. Doroana M, Pinheiro C, Oliveira J, Mansinho K, Germano I, Fonseca P, et al. Comparing treatment of HIV-1 and HIV-2 patients with raltegravir plus OBT. 6th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention; 17-20 July 2011; Rome, Italy.
21. Francisci D, Martinelli L, Weimer LE, Zazzi M, Floridia M, Masini G, et al. HIV-2 infection, end-stage renal disease and protease inhibitor intolerance: which salvage regimen? Clin Drug Investig. 2011;31:345-9.
22. Zheng Y, Lambert C, Arendt V, Seguin-Devaux C. Virological and immunological outcomes of elvitegravir-based regimen in a treatment-naive HIV-2-infected patient. AIDS. 2014;28:2329-31.
23. Povoas D, Lino S, Manata MJ, Machado J, Maltez F. Raltegravir in the treatment of HIV-2 infection: a report of eight cases. Int J Med Pharm Case Rep. 2015;2:36-43.
24. Wandeler G, Furrer H, Rauch A. Sustained virological response to a raltegravir-containing salvage therapy in an HIV-2-infected patient. AIDS. 2011;25:2306-8.
25. Armstrong-James D, Stebbing J, Scourfield A, Smit E, Ferns B, Pillay D, et al. Clinical outcome in resistant HIV-2 infection treated with raltegravir and maraviroc. Antiviral Res. 2010;86:224-6.
26. Cavaco-Silva J, Abecasis A, Miranda AC, Pocas J, Narciso J, Aguas MJ, et al. HIV-2 integrase polymorphisms and longitudinal genotypic analysis of HIV-2 infected patients failing a raltegravir-containing regimen. PLoS One. 2014;9:e92747.
27. Damond F, Lariven S, Roquebert B, Males S, Peytavin G, Morau G, et al. Virological and immunological response to HAART regimen containing integrase inhibitors in HIV-2-infected patients. AIDS. 2008;22:665-6.
28. Garrett N, Xu L, Smit E, Ferns B, El-Gadi S, Anderson J. Raltegravir treatment response in an HIV-2 infected patient: a case report. AIDS. 2008;22:1091-2.
29. Charpentier C, Roquebert B, Delelis O, Larrouy L, Matheron S, Tubiana R, et al. Hot spots of integrase genotypic changes leading to HIV-2 resistance to raltegravir. Antimicrob Agents Chemother. 2011;55:1293-5.
30. Xu L, Anderson J, Garrett N, Ferns B, Wildfire A, Cook P, et al. Dynamics of raltegravir resistance profile in an HIV type 2-infected patient. AIDS Res Hum Retroviruses. 2009;25:843-7.
31. Roquebert B, Blum L, Collin G, Damond F, Peytavin G, Leleu J, et al. Selection of the Q148R integrase inhibitor resistance mutation in a failing raltegravir containing regimen. AIDS. 2008;22:2045-6.
32. Trevino A, de Mendoza C, Caballero E, Rodriguez C, Parra P, Benito R, et al. Drug resistance mutations in patients infected with HIV-2 living in Spain. J Antimicrob Chemother. 2011;66:1484-8.
33. Salgado M, Toro C, Simon A, Garrido C, Blanco F, Soriano V, et al. Mutation N155H in HIV-2 integrase confers high phenotypic resistance to raltegravir and impairs replication capacity. J Clin Virol. 2009;46:173-5.
34. Trevino A, Parra P, Cabezas T, Lozano AB, Garcia-Delgado R, Force L, et al. Drug resistance mutations in HIV-2 patients failing raltegravir - extent of cross-resistance to dolutegravir. Antivir Ther. 2013;18 Suppl 1:A105.
35. Ni XJ, Delelis O, Charpentier C, Storto A, Collin G, Damond F, et al. G140S/Q148R and N155H mutations render HIV-2 Integrase resistant to raltegravir whereas Y143C does not. Retrovirology. 2011;8:68.
36. Grobler JA, Hazuda DJ. Resistance to HIV integrase strand transfer inhibitors: in vitro findings and clinical consequences. Curr Opin Virol. 2014;8C:98-103.
37. Hurt CB, Sebastian J, Hicks CB, Eron JJ. Resistance to HIV integrase strand transfer inhibitors among clinical specimens in the United States, 2009-2012. Clin Infect Dis. 2014;58:423-31.
38. Abram ME, Hluhanich RM, Goodman DD, Andreatta KN, Margot NA, Ye L, et al. Impact of primary elvitegravir resistance-associated mutations in HIV-1 integrase on drug susceptibility and viral replication fitness. Antimicrob Agents Chemother. 2013;57:2654-63.
39. Menendez-Arias L. Molecular basis of human immunodeficiency virus type 1 drug resistance: overview and recent developments. Antiviral Res. 2013;98:93-120.
40. Huang W, Frantzell A, Fransen S, Petropoulos CJ. Multiple genetic pathways involving amino acid position 143 of HIV-1 integrase are preferentially associated with specific secondary amino acid substitutions and confer resistance to raltegravir and cross-resistance to elvitegravir. Antimicrob Agents Chemother. 2013;57:4105-13.
41. Geretti AM, Armenia D, Ceccherini-Silberstein F. Emerging patterns and implications of HIV-1 integrase inhibitor resistance. Curr Opin Infect Dis. 2012;25:677-86.
42. Wainberg MA, Mesplede T, Quashie PK. The development of novel HIV integrase inhibitors and the problem of drug resistance. Curr Opin Virol. 2012;2:656-62.
43. Winters MA, Lloyd Jr RM, Shafer RW, Kozal MJ, Miller MD, Holodniy M. Development of elvitegravir resistance and linkage of integrase inhibitor mutations with protease and reverse transcriptase resistance mutations. PLoS One. 2012;7:e40514.
44. Mesplede T, Quashie PK, Wainberg MA. Resistance to HIV integrase inhibitors. Curr Opin HIV AIDS. 2012;7:401-8.
45. Garrido C, Villacian J, Zahonero N, Pattery T, Garcia F, Gutierrez F, et al. Broad phenotypic cross-resistance to elvitegravir in HIV-infected patients failing on raltegravir-containing regimens. Antimicrob Agents Chemother. 2012;56:2873-8.
46. Blanco JL, Varghese V, Rhee SY, Gatell JM, Shafer RW. HIV-1 integrase inhibitor resistance and its clinical implications. J Infect Dis. 2011;203:1204-14.
47. Kobayashi M, Yoshinaga T, Seki T, Wakasa-Morimoto C, Brown KW, Ferris R, et al. In vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor. Antimicrob Agents Chemother. 2011;55:813-21.
48. da Silva D, Van Wesenbeeck L, Breilh D, Reigadas S, Anies G, Van Baelen K, et al. HIV-1 resistance patterns to integrase inhibitors in antiretroviral-experienced patients with virological failure on raltegravir-containing regimens. J Antimicrob Chemother. 2010;65:1262-9.
49. Goethals O, Clayton R, Van Ginderen M, Vereycken I, Wagemans E, Geluykens P, et al. Resistance mutations in human immunodeficiency virus type 1 integrase selected with elvitegravir confer reduced susceptibility to a wide range of integrase inhibitors. J Virol. 2008;82:10366-74.
50. Marinello J, Marchand C, Mott BT, Bain A, Thomas CJ, Pommier Y. Comparison of raltegravir and elvitegravir on HIV-1 integrase catalytic reactions and on a series of drug-resistant integrase mutants. Biochemistry. 2008;47:9345-54.
51. Charpentier C, Larrouy L, Collin G, Damond F, Matheron S, Chene G, et al. In-vitro phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitor S/GSK1349572. AIDS. 2010;24:2753-5.
52. Tivicay Package Insert. [ http://www.gsksource.com/gskprm/htdocs/documents/TIVICAY-PI-PIL.PDF ]
53. Underwood MR, Johns BA, Sato A, Martin JN, Deeks SG, Fujiwara T. The activity of the integrase inhibitor dolutegravir against HIV-1 variants isolated from raltegravir-treated adults. J Acquir Immune Defic Syndr. 2012;61:297-301.
54. Canducci F, Ceresola ER, Boeri E, Spagnuolo V, Cossarini F, Castagna A, et al. Cross-resistance profile of the novel integrase inhibitor Dolutegravir (S/GSK1349572) using clonal viral variants selected in patients failing raltegravir. J Infect Dis. 2011;204:1811-5.
55. Canducci F, Ceresola ER, Saita D, Castagna A, Gianotti N, Underwood M, et al. In vitro phenotypes to elvitegravir and dolutegravir in primary macrophages and lymphocytes of clonal recombinant viral variants selected in patients failing raltegravir. J Antimicrob Chemother. 2013;68:2525-32.
56. Mesplede T, Osman N, Wares M, Quashie PK, Hassounah S, Anstett K, et al. Addition of E138K to R263K in HIV integrase increases resistance to dolutegravir, but fails to restore activity of the HIV integrase enzyme and viral replication capacity. J Antimicrob Chemother. 2014;69:2733-40.
57. Carganico A, Dupke S, Ehret R, Berg T, Baumgarten A, Obermeier M, et al. New dolutegravir resistance pattern identified in a patient failing antiretroviral therapy. J Int AIDS Soc. 2014;17:19749.
58. Cutillas V, Mesplede T, Anstett K, Hassounah S, Wainberg MA. The addition of R262K to the H51Y mutation in HIV-1 subtype B integrase confers low-level resistance against dolutegravir. Antimicrob Agents Chemother. 2014;59:310-6.
59. Mesplede T, Quashie PK, Osman N, Han Y, Singhroy DN, Lie Y, et al. Viral fitness cost prevents HIV-1 from evading dolutegravir drug pressure. Retrovirology. 2013;10:22.
60. Quashie PK, Mesplede T, Han YS, Oliveira M, Singhroy DN, Fujiwara T, et al. Characterization of the R263K mutation in HIV-1 integrase that confers low-level resistance to the second-generation integrase strand transfer inhibitor dolutegravir. J Virol. 2012;86:2696-705.
61. Wares M, Mesplede T, Quashie PK, Osman N, Han Y, Wainberg MA. The M50I polymorphic substitution in association with the R263K mutation in HIV-1 subtype B integrase increases drug resistance but does not restore viral replicative fitness. Retrovirology. 2014;11:7.
62. Eron JJ, Clotet B, Durant J, Katlama C, Kumar P, Lazzarin A, et al. Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING Study. J Infect Dis. 2013;207:740-8.
63. Hardy I, Brenner B, Quashie P, Thomas R, Petropoulos C, Huang W, et al. Evolution of a novel pathway leading to dolutegravir resistance in a patient harbouring N155H and multiclass drug resistance. J Antimicrob Chemother. 2014;70:405-11.
64. Castagna A, Maggiolo F, Penco G, Wright D, Mills A, Grossberg R, et al. Dolutegravir in antiretroviral-experienced patients with raltegravir- and/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study. J Infect Dis. 2014;210:354-62.
65. Trevino A, Cabezas T, Lozano AB, Garcia-Delgado R, Force L, Fernandez-Montero JM, et al. Dolutegravir for the treatment of HIV-2 infection. J Clin Virol. 2015;64:12-5.
66. Descamps D, Peytavin G, Damond F, Tubiana R, Campa P, Khuong MA, et al. Dolutegravir in the French Early Access Program in Integrase HIV-2-Resistant Infected Patients. 21st Conference on Retroviruses and Opportunistic Infections; 3-6 March 2014; Boston, MA.
67. Gottlieb GS, Smith RA, Dia Badiane NM, Ba S, Hawes SE, Toure M, et al. HIV-2 integrase variation in integrase inhibitor-naive adults in Senegal, West Africa. PLoS One. 2011;6:e22204.
68. Foley B, Leitner T, Apetrei C, Hahn B, Mizrachi I, Mullins J, et al. HIV Sequence Compendium 2013. Los Alamos, NM: Theoretical Biology and Biophysics Group, Los Alamos National Laboratory; 2013.
69. Fikkert V, Hombrouck A, Van Remoortel B, De Maeyer M, Pannecouque C, De Clercq E, et al. Multiple mutations in human immunodeficiency virus-1 integrase confer resistance to the clinical trial drug S-1360. AIDS. 2004;18:2019-28.
70. Kobayashi M, Nakahara K, Seki T, Miki S, Kawauchi S, Suyama A, et al. Selection of diverse and clinically relevant integrase inhibitor-resistant human immunodeficiency virus type 1 mutants. Antiviral Res. 2008;80:213-22.
71. Nguyen TT, Rato S, Molina JM, Clavel F, Delaugerre C, Mammano F: Impact of the HIV integrase genetic context on the phenotypic expression and in vivo emergence of raltegravir resistance mutations. J Antimicrob Chemother 2015. doi:10.1093/jac/dku424
72. Quashie PK, Oliviera M, Veres T, Osman N, Han Y, Hassounah S, et al. Differential effects of the G118R, H51Y and E138K resistance substitutions in HIV integrase of different subtypes. J Virol 2014. doi:10.1128/JVI.03353-14
73. Malet I, Gimferrer Arriaga L, Artese A, Costa G, Parrotta L, Alcaro S, et al. New raltegravir resistance pathways induce broad cross-resistance to all currently used integrase inhibitors. J Antimicrob Chemother. 2014;69:2118-22.